These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21999537)

  • 1. Synthetic neoglycoconjugates of cell-surface phosphoglycans of Leishmania as potential anti-parasite carbohydrate vaccines.
    Nikolaev AV; Sizova OV
    Biochemistry (Mosc); 2011 Jul; 76(7):761-73. PubMed ID: 21999537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The preparation of neoglycoconjugates containing inter-saccharide phosphodiester linkages as potential anti-Leishmania vaccines.
    Routier FH; Nikolaev AV; Ferguson MA
    Glycoconj J; 1999 Dec; 16(12):773-80. PubMed ID: 11133017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipophosphoglycan of the protozoan parasite Leishmania: stage- and species-specific importance for colonization of the sandfly vector, transmission and virulence to mammals.
    Ilg T
    Med Microbiol Immunol; 2001 Nov; 190(1-2):13-7. PubMed ID: 11770101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoconjugates in Leishmania infectivity.
    Descoteaux A; Turco SJ
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):341-52. PubMed ID: 10571023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of the major cell surface glycoconjugates of Leishmania parasites by the human serum mannan-binding protein.
    Green PJ; Feizi T; Stoll MS; Thiel S; Prescott A; McConville MJ
    Mol Biochem Parasitol; 1994 Aug; 66(2):319-28. PubMed ID: 7808481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania lipophosphoglycan components: A potent target for synthetic neoglycoproteins as a vaccine candidate for leishmaniasis.
    Mohammed ASA; Tian W; Zhang Y; Peng P; Wang F; Li T
    Carbohydr Polym; 2020 Jun; 237():116120. PubMed ID: 32241437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies directed against Leishmania secreted acid phosphatase and lipophosphoglycan. Partial characterization of private and public epitopes.
    Ilg T; Harbecke D; Wiese M; Overath P
    Eur J Biochem; 1993 Oct; 217(2):603-15. PubMed ID: 7693464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parasite glycoconjugates. Part 16: Synthesis of a disaccharide and phosphorylated di- and tri-saccharides from Leishmania lipophosphoglycan.
    Ross AJ; Sizova OV; Nikolaev AV
    Carbohydr Res; 2006 Aug; 341(11):1954-64. PubMed ID: 16697981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lipophosphoglycan of Leishmania parasites.
    Turco SJ; Descoteaux A
    Annu Rev Microbiol; 1992; 46():65-94. PubMed ID: 1444269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania lipophosphoglycan: how to establish structure-activity relationships for this highly complex and multifunctional glycoconjugate?
    Forestier CL; Gao Q; Boons GJ
    Front Cell Infect Microbiol; 2014; 4():193. PubMed ID: 25653924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycoconjugates in New World species of Leishmania: polymorphisms in lipophosphoglycan and glycoinositolphospholipids and interaction with hosts.
    de Assis RR; Ibraim IC; Nogueira PM; Soares RP; Turco SJ
    Biochim Biophys Acta; 2012 Sep; 1820(9):1354-65. PubMed ID: 22093608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination in Leishmaniasis: A Review Article.
    Abdellahi L; Iraji F; Mahmoudabadi A; Hejazi SH
    Iran Biomed J; 2022 Jan; 26(1):1-35. PubMed ID: 34952558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential modulation of macrophage response elicited by glycoinositolphospholipids and lipophosphoglycan from Leishmania (Viannia) shawi.
    Passero LF; Assis RR; da Silva TN; Nogueira PM; Macedo DH; Pessoa NL; Campos MA; Laurenti MD; Soares RP
    Parasitol Int; 2015 Aug; 64(4):32-5. PubMed ID: 25619843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular variation in Leishmania.
    Moody SF
    Acta Trop; 1993 May; 53(3-4):185-204. PubMed ID: 8100670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developmentally regulated changes in the cell surface architecture of Leishmania parasites.
    McConville MJ; Ralton JE
    Behring Inst Mitt; 1997 Mar; (99):34-43. PubMed ID: 9303200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iterative synthesis of Leishmania phosphoglycans by solution, solid-phase, and polycondensation approaches without involving any glycosylation.
    Ruhela D; Vishwakarma RA
    J Org Chem; 2003 May; 68(11):4446-56. PubMed ID: 12762750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure, functions, and biosynthesis of glycoconjugates of Leishmania spp. cell surface.
    Novozhilova NM; Bovin NV
    Biochemistry (Mosc); 2010 Jun; 75(6):686-94. PubMed ID: 20636259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Parasitic evasion mechanisms: Leishmania as an example].
    Solbach W; Bogdan C; Moll H; Lohoff M; Röllinghoff M
    Immun Infekt; 1989 Aug; 17(4):129-40. PubMed ID: 2673994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipophosphoglycan (LPG) and the identification of virulence genes in the protozoan parasite Leishmania.
    Beverley SM; Turco SJ
    Trends Microbiol; 1998 Jan; 6(1):35-40. PubMed ID: 9481823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins.
    Russo DM; Turco SJ; Burns JM; Reed SG
    J Immunol; 1992 Jan; 148(1):202-7. PubMed ID: 1370169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.